TheChek News Flow

Gapping down
In reaction to earnings/guidance:

• JRVR -23.9% (also announced $175 mln stock offering), FSLY -18.4% (also CFO to step down), RKT -12.9%, YELL -12.8%, ETSY -11.1%, VAPO -9.8%, AVNW -9.5%, TXG -8.7%, CAH -8.2%, CENX -7.1%, TWO -6.5%, RDFN -6.1%, IIVI -5.9%, MTW -5.4%, MRNA -5.4%, CTSH -4.9%, INSG -4.9%, TWLO -4.9%, GKOS -4.8%, FATE -4.8%, PWR -4.5%, CCMP -4.2%, USCR -4.2%, UBER -3.9%, NCLH -3.9%, LOPE -3.7%, SRPT -3.3%, APTV -3.3%, ACIW -3.1%, W -2.9%, LAUR -2.9%, KW -2.8%, ALE -2.4%, GOGO -2.4%, FMC -2.3%, EVRG -2.3%, MIDD -2.3%, MTG -2.2%, GDOT -2.2%, GBT -2.1%, WD -2%, KL -2%, TPR -2%, XEC -1.9%, CXW -1.6%, PENN -1.6%, AVYA -1.6%, DCP -1.5%, KRO -1.5%, ING -1.3%, HWM -1.3%, ALB -1.2%, CF -1.2%, EQT -1.1%, MET -1.1%, BE -1.1%, FLT -1%

Other news:

• NVAX -7.1% (announces publication of results for Phase 2b trial conducted in South Africa of NVX-CoV2373)
• ALGT -6.4% (prices offering of 1.35 mln shares of common stock at $219.00 per share)
• MRK -1.1% (FDA approves KEYTRUDA for HER2-positive gastric or gastroesophageal junction adenocarcinoma)
• BE -1.1% (BKR and BE to collaborate on efficient power and hydrogen solutions)
• AMT -1% (prices offering of 9 mln shares of common stock at $244.75 per share)

Analyst comments:

• FMC -2.3% (downgraded to Neutral from Buy at Citigroup)
• PTON -2.3% (downgraded to Neutral from Buy at BofA Securities)
• PFE -1.9% (downgraded to Neutral from Buy at Mizuho)
• OCFC -1.4% (downgraded to Equal-Weight from Overweight at Stephens)

Gapping up
In reaction to earnings/guidance:

• CDNA +16.2%, QLYS +11.3%, HIMX +10.7%, AVID +10.4%, ARLO +9.7%, SBH +8.6%, BCRX +8.5%, GIL +8.1%, RUN +6.5%, RLJ +6.1%, CDAY +6.1%, ZNGA +5.6% (also to acquire Chartboost), AOSL +5.3%, HEAR +5.1%, OSUR +5.1%, QTWO +5%, BUD +5%, PRIM +4.6%, PYPL +4.6%, PZZA +4.2%, NUS +4%, SIMO +3.9%, ROOT +3.7%, APA +3.7%, TNDM +3.6%, DGII +3.5%, CCRN +3.5%, FVRR +3.3%, VSTO +3.3%, CSGS +3.1%, TMX +3.1%, TEN +3.1%, HUBS +3%, CARS +3%, BLDR +2.9%, VIAC +2.9%, BKI +2.9%, PDCE +2.8%, VNT +2.8%, NVST +2.7%, FRT +2.6%, BLD +2.6%, BAND +2.5%, IRM +2.5%, MELI +2.2%, RCII +2.2%, AES +2.2%, XXII +2.2%, PING +2.1%, STAA +2.1%, WCC +2.1%, ADNT +2.1%, COMM +2%, HL +1.9%, EPAM +1.9%, NRG +1.9%, WBT +1.7%, ICPT +1.7%, NBIX +1.5%, RSG +1.5%, AG +1.5%, ECOM +1.4%, QRVO +1.3%, UGI +1.3% (also increases dividend), MT +1.3%, RGR +1.2%, SKT +1.2%, PRLB +1.2%, MDU +1.1%, MGA +1.1%, PQG +1.1%, STOR +1.1%, VG +1.1%, MMS +1%

Other news:

• LKCO +24.3% (announces favorable court ruling granting preliminary injunction)
• HOME +16.5% (in talks with Hellman & Friedman for take-private deal, according to WSJ)
• ORGS +11.2% (has been granted Investigational Device Exemption approval by the United States Food and Drug Administration to conduct a first-in-human feasibility study of the Tissue Genesis Icellator2 to treat Acute Respiratory Distress Syndrome resulting from COVID-19 infection)
• TRVN +9.6% (announces selection of TRV027 for NIH-funded ACTIV initiative for COVID-19 trial)
• MNOV +4.5% (receives Notice of Intention to Grant from the European Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis)
• AGTC +4.4% (reports "positive" 12-month data from highest dose groups in its ongoing XLRP Phase 1/2 clinical trial)
• CWH +4% (to acquire Hilmerson RV)
• CEQP +3.8% (files for 6 mln common unit offering by selling shareholders)
• KLR +3.8% (to build communication solutions with Trellance for credit unions)
• ASO +2.8% (prices offering of 14 mln shares of common stock at $32.00 per share)
• ADCT +2.2% (ZYNLONTA has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines in oncology for B-cell Lymphomas) AG +1.5% (files for US$300 mln mixed securities shelf offering)
• LGIH +1.4% (reports April 2021 home closings)
• APEN +1.3% (files for $150 mln mixed securities shelf offering)

Analyst comments:

• PSNL +7.5% (upgraded to Outperform from Perform at Oppenheimer)
• RARE +5.8% (upgraded to Buy from Neutral at Citigroup)
• CMLS +4.9% (upgraded to Buy from Neutral at B. Riley Securities)
• EOLS +3.6% (upgraded to Buy from Neutral at Mizuho)
• WOW +3.3% (upgraded to Overweight from Equal-Weight at Stephens)
• FRT +2.6% (upgraded to Overweight from Neutral at Piper Sandler)
• MRCY +1.9% (upgraded to Buy from Hold at Jefferies)
• DRI +1.3% (upgraded to Outperform from Market Perform at Cowen)
• FLEX +1.3% (upgraded to Buy from Hold at Cross Research)
• NGG +1.1% (upgraded to Buy from Hold at Berenberg)
• ASTE +1% (upgraded to Buy from Hold at Stifel)

Early premarket gappers

• Gapping up:
  • CDNA +16.2%, HOME +15.3%, QLYS +10.3%, AVID +10.1%, ARLO +9.2%, GIL +8.1%, CDAY +8.1%, MNOV +7.1%, RUN +5.8%, HEAR +5.8%, AOSL +5.3%, BUD +5.2%, ZNGA +5.1%, OSUR +5.1%, STAA +5%, FVRR +5%, QTWO +4.8%, PRIM +4.6%, PYPL +4.4%, CWH +4%, NUS +4%, CEQP +3.8%, CUTR +3.8%, KLR +3.8%, ECPG +3.6%, TNDM +3.6%, DGII +3.5%, WCC +3.3%, HIMX +3.3%, CSGS +3.1%, HUBS +3%, CCRN +3%, HL +3%, VSTO +2.9%, NVST +2.7%, SIMO +2.6%, KLIC +2.6%, PDCE +2.5%, SGMO +2.4%, WW +2.4%, OBSV +2.4%, ZYNE +2.3%, ADCT +2.2%, BE +2.2%, RCII +2.2%, VNT +2.2%, AES +2.2%, PING +2.1%, COMM +2%, EPAM +1.9%, MGA +1.8%, FRT +1.7%, WBT +1.7%, XXII +1.7%, XRAY +1.6%, LGIH +1.4%, BKR +1.4%, APEN +1.3%, MRO +1.3%, QRVO +1.3%, UGI +1.3%, MELI +1.3%, RGR +1.2%, BAND +1.2%, SKT +1.2%, MDU +1.1%, MUR +1.1%, PQG +1.1%
• Gapping down:
  • JRVR -24.7%, FSLY -16.7%, RKT -14.2%, AVNW -13.3%, YELL -13.2%, ETSY -11.2%, VAPO -9.8%, KTOS -8.7%, INSG -7%, TXG -6.4%, TWO -6.1%, CENX -5.7%, NVAX -5.6%, CTSH -5.5%, RDFN -5.4%, ALGT -5.1%, GKOS -4.8%, TWLO -4.7%, LOPE -4.6%, GDDY -4.3%, CCMP -4.2%, MTW -4.1%, FATE -3.8%, UBER -3.5%, SRPT -3.3%, LESL -3.2%, ACIW -3.1%, KW -2.8%, XEC -2.7%, ALE -2.4%, GBT -2.1%, MRNA -2%, FMC -2%, KL -2%, PLYA -1.9%, MTG -1.9%, ASO -1.7%, CXW -1.6%, SUPN -1.6%, DCP -1.5%, KRO -1.5%, PRLB -1.3%, AMT -1.2%, CF -1.2%, ATSG -1.2%, USCR -1.2%, UMC -1.1%, FLT -1%, ING -1%, ICL -1%